Search research articles
Contact Us
Filters
Showing results (231-240 of 635) with videos related to
Page
of 64
Sort By:
Circulation
|
June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Diabetes, Obesity & Metabolism
|
March 28, 2023
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial
Tae Won Yi, Michelle M Y Wong, Brendon L Neuen, et al.
European Heart Journal
|
April 5, 2007
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
Chadwick D Miller, Anindita Banerjee, Kenneth W Mahaffey, et al.
European Heart Journal
|
September 12, 2018
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
Gregg W Stone, Philippe Généreux, Robert A Harrington, et al.
Journal of the American College of Cardiology
|
September 4, 2016
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings
Senthil Selvaraj, Deepak L Bhatt, Gregg W Stone, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 31, 2023
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Sjoukje van der Hoek, Niels Jongs, Megumi Oshima, et al.
International Journal of Cardiology
|
October 15, 2017
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
Alon Eisen, Robert A Harrington, Gregg W Stone, et al.
Circulation
|
June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial
Kenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
International Journal of Cardiology
|
June 23, 2020
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
Clare Arnott, Brendon L Neuen, Hiddo J L Heerspink, et al.
Journal of Medical Internet Research
|
December 20, 2024
Resting Heart Rate and Associations With Clinical Measures From the Project Baseline Health Study: Observational Study
Kent Y Feng, Sarah A Short, Sohrab Saeb, et al.
Page
of 64
Search research articles
Search
Showing results (231-240 of 635) with videos related to
Sort By:
Page
of 64
Circulation
|
June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Diabetes, Obesity & Metabolism
|
March 28, 2023
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial
Tae Won Yi, Michelle M Y Wong, Brendon L Neuen, et al.
European Heart Journal
|
April 5, 2007
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial
Chadwick D Miller, Anindita Banerjee, Kenneth W Mahaffey, et al.
European Heart Journal
|
September 12, 2018
Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
Gregg W Stone, Philippe Généreux, Robert A Harrington, et al.
Journal of the American College of Cardiology
|
September 4, 2016
"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings
Senthil Selvaraj, Deepak L Bhatt, Gregg W Stone, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 31, 2023
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Sjoukje van der Hoek, Niels Jongs, Megumi Oshima, et al.
International Journal of Cardiology
|
October 15, 2017
Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials
Alon Eisen, Robert A Harrington, Gregg W Stone, et al.
Circulation
|
June 29, 2011
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial
Kenneth W Mahaffey, Daniel M Wojdyla, Kevin Carroll, et al.
International Journal of Cardiology
|
June 23, 2020
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
Clare Arnott, Brendon L Neuen, Hiddo J L Heerspink, et al.
Journal of Medical Internet Research
|
December 20, 2024
Resting Heart Rate and Associations With Clinical Measures From the Project Baseline Health Study: Observational Study
Kent Y Feng, Sarah A Short, Sohrab Saeb, et al.
Page
of 64